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Abstract
Background and purpose Activation of the transcription
factor NF-κB by proteasomes and subsequent nuclear trans-
location of cytoplasmatic complexes play a crucial role in the
intestinal inflammation. Proteasomes have a pivotal function
in NF-κB activation by mediating degradation of inhibitory
IκBproteinsandprocessingofNF-κBprecursorproteins.This
studyaims to analyze theexpressionofthehuman proteasome
subunits in colonic tissue of patients with Crohn’s disease.
Materials and methods Thirteen patients with Crohn’s
disease and 12 control patients were studied. The expression
of immunoproteasomes and constitutive proteasomes was
examined by Western blot analysis, immunoflourescence and
quantitative real-time PCR. For real-time PCR, AK2C was
used as housekeeping gene.
Results The results indicate the influence of the intestinal
inflammation on the expression of the proteasomes in
Crohn’s disease. Proteasomes from inflamed intestine of
patients with Crohn’s disease showed significantly in-
creased expression of immunosubunits on both protein
and mRNA levels. Especially, the replacement of the
constitutive proteasome subunit β1 by inducible immuno-
subunit β1i was observed in patients with active Crohn’s
disease. In contrast, relatively low abundance of immuno-
proteasomes was found in control tissue.
Conclusions Our data demonstrate that in contrast to
normal colonic tissue, the expression of immunoprotea-
somes was evidently increased in the inflamed colonic
mucosa of patients with Crohn’s disease. Thus, the chronic
intestinal inflammation process in Crohn’s disease leads to
significant alterations of proteasome subsets.
Keywords Crohn’sdisease.Inflammatorybowel
disease.26Sproteasome.20Sproteasome.NF-κB
Introduction
Although the etiology of Crohn’s disease (CD) still remains
partially unclear, substantial advances have been made
recently in both understanding of the molecular pathogenesis
and also in the development of new therapeutic strategies.
The uncontrolled activation of proinflammatory effector
CD4
+ T cells seems to be a pivotal pathogenic mechanism
associated with initiation and perpetuation of the inflamma-
tory process. Activation of Th1 CD4
+ T cells as well as of
macrophages and dendritic cells leads to the increased
production of proinflammatory cytokines in the inflamed
intestinal mucosa in Crohn’s disease [1–3]. The range of
effector CD4
+ subsets has recently expanded with the
description of Th17 cells, which produce cytokines IL-17,
IL-17F, and IL-22 [4–6]. The proinflammatory cytokines
IL-12, which is important for differentiation of Th1 cells, and
recently described IL-23 have been shown to play a crucial
roleinthe pathogenesisofCD.Novel studiesinmurinecolitis
models resembling human CD suggest that IL-23 is the
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and to drive the regional intestinal inflammation [7, 8].
Studies in mice have shown that different members of
NF-κBfamilyplayapivotalroleindefense ofthehostagainst
the pathogens by regulating of proinflammatory gene expres-
sion [9]. Synthesis of most important proinflammatory
cytokines and chemokines such as IL-12, IL-23, TNF-α,I L - 6 ,
IL-8, and IL-1β is mediated by NF-κB. Increased NF-κB
activity with nuclear localization was observed in inflammatory
boweldisease,especiallyinCD[10–12]. Proteasome is essential
for IKKβ-induced NF-κB activation contributing directly to
the activation of NF-κB by mediating degradation of
inhibitory NF-κB proteins of IκB family and the process-
ing of NF-κB precursor proteins p105 and p100 [13].
Therefore, the proteasome represents a potential target for
strategies aimed at suppressing inflammation processes.
The eukaryotic 26S proteasome is the main protease in the
cytoplasm and nucleus consisting of a proteolytic core, the 20S
proteasome, and two 19S regulatory particles. The barrel-like
20S proteasome is composed of seven different α and seven
different β subunits which form four rings stacked on top of
eachother[14]. The subunits β1, β2, and β5 bear the catalytic
activity of the proteasome. In vertebrates, there exist three
additional IFN-γ inducible subunits, so-called immunosubu-
nits β1i, β2i, and β5i. IFN-γ inducible substitution of
proteasomal constitutive subunits by immunosubunits changes
the proteolytic specificity of the proteasome and modulates the
generation of the peptides used as ligands for MHC class I
presentation [15, 16]. Even more importantly for inflamma-
tory processes, the induction of proteasomal immunosubu-
nits is associated with increased NF-κBa c t i v i t y[ 11, 17].
It has been shown that the constitutive proteasome is the
predominant form in most tissues [18]. In the course of
infection, IFN-γ induces the expression of immunoprotea-
somes in affected tissues [19]. Since the levels of IFN-γ are
also elevated in CD, we decided to evaluate the possible effects
of the inflammation on the expression of proteasomes in the
intestine. In the present study, the relationship of proteasomal
mRNA levels and abundance of encoded proteins in normal
and inflamed colonic tissue have been analyzed. In particular,
we compared the mRNA and protein expression of protea-
somes of patients with CD with a control group of patients.
Materials and methods
Patients
Colonic mucosa specimens from patients with Crohn’s
disease were obtained from surgical resections after
intestinalsurgeryperformedattheCharitéUniversityHospital,
Berlin. Control specimens were obtained from patients
undergoing surgery for colorectal cancer (macroscopically
and histologically non-affected normal colonic tissue). A total
group of 13 patients with active CD and 12 control patients
was investigated. In all cases, diagnosis of CD was confirmed
histologically using scoring systems for CD: 0 = normal; 1 =
mild edema and mild inflammation in the lamina propria; 2 =
crypt abscesses and moderate inflammation of the lamina
propria; 3 = more severe inflammation with destructive crypt
abscesses (±granulomata); 4 = strong inflammation with
ulcerations or fissures.Immediatelyafterthesurgery, intestinal
mucosa was separated from the underlying tissue and used for
the experiments. In all 13 CD patients, histology revealed
severe inflammation with histological scores of 3 (n=7) and 4
(n=6), respectively. Informed consent was obtained from all
patients, and the protocol was approved by the local ethics
committee.
Preparation of protein extracts from human colonic tissue
For the preparation of organ lysates, colonic mucosa was
striped from the submucosa, frozen in liquid nitrogen and
stored at −196°C until use. Colonic mucosa was homoge-
nized with mortar and pestle followed with 20 strokes of
the dauncer and subsequently immersed in ice-cold Lysis
Buffer (20 mM Tris–HCl, pH 6,8, 50 mM NaCl, 1 mM
EDTA pH 8, 1 mM NaN3, 1 mM DTT, 0.1% NP-40,
0,2 mM sodium vanadate, 10 mM sodium fluoride, 1 mM
PMSF). 1× complete protease inhibitor (Roche Applied
Science, Mannheim, Germany) was added into lysis buffer.
Samples were incubated on ice for 20 min and cell debris
was sedimented by centrifugation at 13,000×g for 10 min.
Supernatants were used as cell lysates.
Western blot analysis
For the detection of proteasomal proteins β1 and β1i, the
color fluorescent Western blot analysis was performed.
Briefly, for the cell lysates the protein concentration was
determined using Micro BCA Protein Assay Kit (Pierce
biotechnology, Rockford, IL, USA) and subsequently 20μg
of total protein was denaturated in 4× Laemmli Buffer and
separated by 15 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Following SDS-PAGE,
samples were transferred to Immobilon
FL polyvinylidene
difluoride (PVDF) membrane (Millipore, Bedford, MA,
USA) at 100 V in transfer buffer (50 mM Tris, 40 mM
glycine, 0.037% (w/v) SDS, 20% (v/v)m e t h a n o l )f o r6 0m i n .
Membranes were blocked for 30 min in an Odyssey
Blocking Reagent (Licor Bioscience, Lincoln, NE, USA)
and then incubated for 1 h with the appropriate primary
antibody. As control for protein amounts a monoclonal anti-
human β-actin antibody (Sigma-Aldrich, Munich, Germany)
diluted 5,000-fold in Odyssey Blocking Reagent was used.
β1a n dβ1i were detected using rabbit polyclonal anti-
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1,000-fold in the same buffer. Visualization was performed
by using fluorescence-labeled secondary antibodies, goat-
anti rabbit IRDye 800 (Rockland, Gilbertsville, PA, USA)
and AlexaFluor 680 (Molecular Probes Eugene, OR, USA),
respectively. The detection was performed using Odyssey
infrared imaging system (Licor Biosciences, Lincoln, NE,
USA).
Quantitative real-time PCR
Quantitative real-time PCR analysis for proteasomal sub-
units was performed by using an ABI Prism 7000 sequence
detection system (Applied Biosystems, Forster city, CA,
USA) according to manufacturer´s instructions. Primers
were manufactured by TIBMolbiol (Berlin, Germany).
AK2C was used as a housekeeping gene for standardiza-
tion. The analysis was performed as previously described
[10]. Briefly, colonic mucosa was homogenized in Trizol
(Invitrogen, Carlsbad, CA, USA) and total cellular RNA
was extracted and treated with RNase-free DNase in order
to remove contaminating genomic DNA from the sample.
ThedeterminationofconcentrationandtotalRNAqualitywas
analyzed with the 2100 Bioanalyzer (Aligent Technologies,
Santa Clara, CA, USA). For the cDNA synthesis, 2μg of total
RNAwas reverse transcribed and subsequently real-time PCR
was performed using the SYBR Green Master Mix (Applied
Biosystems, Forster city, CA, USA). During PCR reactions,
the increase in SYBR Green fluorescence is directly propor-
tional to the amount of double-stranded DNA generated; 5µl
cDNA templatediluted1:5 and1:10,10pmolforward primer,
10 pm reverse primer and SYBR Green Mix ready-to-use
solution (2×) in a 30µl final reaction mixture were used. The
evaluation of data was carried out by using SDS2.2.2.
software (Applied Biosystems, Forster city, CA, USA).
Immunofluorescence microscopy
Immunoflourescence staining was performed on intestinal
cryosections of 5µm thickness. For intracellular staining of
proteasome subunit β1i, the sections were washed in PBS
for 5 min, fixed in acetone /methanol (1:1) and permeabi-
lized with 0.1% (v/v) NP40 for 10 min. After permeabi-
lization, normal goat serum was applied for binding
nonspecific antigens. As primary antibody, polyclonal
rabbit anti-β2i (Biomol, Hamburg, Germany) diluted 1:50
was used for 60 min. As negative control, sections were
incubated with antibody diluent without primary antibody.
β2i was detected using secondary Cy2-coupled anti-rabbit
immunoglobulin G (DakoCytomation, Hamburg, Germany)
for 60 min. The sections were analyzed on the fluorescence
microscope Leica DMRB (Leica Microsystems, Wetzler,
Germany).
Statistical analysis
Real-time PCR data were compared using a two-tailed
Student’s t-test. A one-way ANOVAwas used for analyzing
multiple groups. Each set of data was expressed as SEM. P
values ≤0.05 were regarded as statistically significant.
Results
Preferential incorporation of proteasomal immunosubunit
β1i in Crohn’s disease
A previous study has shown that DSS treatment induced
increased expression of β1i in the colon associated with
histological damage in mice, whereas symptoms of DSS-
induced colitis were much milder in β1i-deficient (LMP2
−/−)
mice lacking the β1i subunit [20]. To investigate the
incorporation of distinct proteasomal catalytic subunits into
proteasomes of CD patients, intestinal samples were exam-
ined by Western blotting and real-time PCR. In inflamed
colon of patients with CD and non-inflamed colonic tissue of
control patients, the abundance of the catalytic immunosu-
bunit β1i was examined by Western blot analysis. By using
specific antibody for β1i, a singular band for this protein
was detected at approximately 25 kD. The increased protein
expression of β1i was observed in patients with CD as
compared to control patients (Fig. 1b). In order to analyze
whether the increased incorporation of immunosubunit β1i
into proteasomes in inflamed colonic mucosa of CD patients
is the limiting factor for the expression of its counterpart
protein β1, the whole cell lysates from colonic tissue of CD
and control patients were also tested for β1. In all but one
control patients, the protein levels of this constitutive protea-
somal subunit were higher in control tissue than in inflamed
colonic tissue of patients with CD (Fig. 1a). Thus, the increase
of the β1i protein levels in CD was accompanied with a
significantly decreased abundance of β1( F i g .1a and b).
Inflammation in Crohn’s disease shifts the proteasome
subunit composition towards immunoproteasomes
Since immunoproteasome subunits compete with their
constitutive homologues for incorporation into the nascent
proteasomes, we wondered whether mRNA levels of
catalytic subunits β1i and β1 correlate with protein
expression in CD. To study this, total RNA was extracted
from colonic samples of CD patients and healthy controls
and β1 and β1i mRNAs were quantified by quantitative
real-time PCR. At the same time, we looked at the β1i/β1
ratio of their cellular mRNA levels in CD and controls. In
the inflamed mucosa of CD patients, we observed an
increase of β1i mRNA levels compared with normal
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β1i mRNA to its counterpart β1 mRNA, we observed that
in inflamed tissue of CD patients, threefold more β1i
mRNA was expressed relative to the β1 mRNA, whereas
no significant difference in the expression of β1i and β1
mRNA was observed in normal colonic tissue (Fig. 2b).
These results indicate that due to inflammation significantly
increased expression of β1i mRNA leads to augmented
amounts of β1i protein and that induced overexpression of
β1i prevents incorporation of its constitutive counterpart
β1 into 20S proteasomes in CD.
Interestingly, not only mRNA levels of β1i but also of
β5i were enhanced in CD in comparison to control colonic
tissue. However, β5i mRNA expression was also very high
in normal colonic tissue (Fig. 3a). By examining ratio of
β5i/β5 mRNA in patients with CD and control patients, we
found that mRNA expression of β5i was approximately
fourfold higher than that of mRNA β5 in both groups
(Fig. 3b). Previously, our proteasome analysis of distinct
mouse and human organs by using two-dimensional gel
electrophoresis and mass spectrometry has revealed high
amounts of β5i in normal human intestine [21]. In
accordance with this study, we here detected high β5i
mRNA levels in both inflamed colon of CD and control
non-inflamed colonic tissue, although mRNA expression of
this immunosubunit was even higher in CD (Fig. 3a).
Expression of immunosubunit β2i is increased in Crohn’s
disease
β2i is the third inducible catalytic subunit, which has been
shown to be preferentially incorporated into the imunopro-
teasome [22]. To confirm that the immunoproteasome is
predominant form of proteasomes in inflamed colonic
mucosa of patients with CD we analyzed the protein
expression of the immunosubunit β2i using a polyclonal
rabbit antibody detected by immunofluorence staining.
Analysis of colonic mucosa showed that the lamina propria
cells as well as epithelial cells of the inflamed tissue in CD
were positive after staining of β2i. No β2i expressing
positive cells were visualized in normal colon (Fig. 4).
Thus, we demonstrate here that all three inducible protea-
somal immunosubunits are highly expressed in colonic
mucosa of patients with CD but not in that of control
patients. The β5i was the only immunosubunit also
abundant in normal colon, which indicates that also
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Fig. 2 a Relative mRNA expression of proteasomal subunits β1i and
β1 was analyzed in the colon of controls and CD patients by
quantitative real-time PCR. Data represents means ± SEM (control,
n=12; CD, n=13). After extraction of total RNA, cDNA was
amplified with specific primers for β1i and β1. As housekeeping
gene, AK2C was used. b Ratio of β1i to β1 mRNA expression in
colonic mucosa of controls and CD patients (control, n=12; CD,
n=13). Data are presented as means ± SEM
a                         b
control        Crohn`s disease               control        Crohn`s disease
β
β
-actin β-actin
  1                                            β1i
Fig. 1 Protein expression of the proteasomal subunits β1( a) and β1i
(b) in the inflamed mucosa of CD patients and normal colonic tissue
(control, n=12; CD, n=13). Western blot analysis was performed
using anti-human antibodies for β1i and β1. β-actin was used as
loading control. The results shown above are from three representative
patients. Lanes 1–3, cell extracts of normal colonic mucosa; lane 4–6,
cell extracts of inflamed colonic mucosa of CD patients
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which may have different functions in vivo.
Discussion
There is increasing evidence that primary dysregulation of
the mucosal immune system is one of the most important
factors in the development of CD [23]. Inappropriate
secretion of proinflammatory cytokines and other inflam-
mation mediators by intestinal macrophages, dendritic cells
and T cells has been shown to be responsible for the
immune disturbance in CD [24, 25]. The activation of the
transcription factor NF-κB plays a pivotal role in responses
to inflammatory signaling through Toll-like receptors, TNF
receptor superfamily and the IL-1 receptor [26]. While
someeventstriggeringtheinductionofNF-κBac ti vi tyre ma in
still obscure, it is well-known that ubiqutin-proteasome
system contributes directly to activation of this transcription
factor—and thus to many aspects of inflammatory responses.
The core particle of the enzymatically active 26S proteasome
is the 20S proteasome, a multicatalytic complex composed of
14 different subunits. The two inner rings are formed by the
β-type subunits, of which β1, β2, and β5 are catalytically
active sites [16]. It has been shown that interferon-γ (IFN-
γ), the most important cytokine during viral infection, is the
central molecule causing the alternation of the proteasomal
subunit composition. Upon stimulation of cells with IFN-γ,
the constitutive catalytic subunits β1, β2a n dβ5a r e
replaced with β1i, β2i and β5i, respectively. This replace-
ment of constitutive proteasomes with so-called immuno-
proteasomes is a way that can promote more efficient
generation of epitopes from viral- and tumor-associated
antigens suitable for binding to MHC class I molecules
[27].
For many years IFN-γ has been considered to be one of
the most important cytokines involved in the pathogenesis
of CD [25, 28]. The aim of this study was to investigate the
expression of IFN-γ- inducible proteasome immunosubunits
both at the mRNA and protein level in the inflamed
intestinal mucosa of CD patients. Despite the considerable
variations between individual samples, we were able to find
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Fig. 3 a Relative mRNA expression of proteasomal subunits β5i and
β5 measured in the colonic mucosa of control and CD patients
(control, n=12; CD, n=13). The results are presented as mean ± SEM.
Quantitative real-time PCR was performed using specific primers for
β5i and β5. As housekeeping gene, AK2C was used. b β1i / β1
mRNA expression in inflamed colonic tissue of CD patients and
control colon tissue (control, n=12; CD, n=13). Data are presented as
means ± SEM
DAPI            β β2i
control
Crohn`s disease                
Fig. 4 Immunofluorescence
analysis of proteasomal immu-
nosubunit β2i in the colon of
CD patients and controls
(control, n=12; CD, n=13).
Representative images of stain-
ing for β2i, magnification,
×200. Increased expression of
β2i was observed in CD patients
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when compared with control patients. Inflamed tissue of
patient with CD showed markedly increased levels of
immunoproteasomes. An important finding of this study is
the pronouncedly high mRNA expression of all three
immunosubunits β1i, β2i and β5i in CD. Interestingly, at
the mRNA level, inflammation induces not only immuno-
subunits but to less extent also constitutive catalytic subunits.
However, the induction of immunosubunit mRNAs was
significantly stronger resulting in the replacement of consti-
tutive proteasomal proteins by their homologous counter-
parts. Western blot analysis of the subunits β1i and β1
clearly showed that the chronic inflammation in Crohn’s
disease shifts the proteasome subunit expression towards
immunoproteasomes at the protein level. Since IFN-γ has
been shown to be the main inducer of immunoproteasomes
in various murine and human cell lines and the IFN-γ levels
are highly elevated in inflamed intestine of CD patients, we
suppose that induction of immunoproteasomes in CD is
mediated by this cytokine. However, relatively high consti-
tutive expression of mRNA β5i was also observed in the
control colonic tissue. In accordance with this finding, it has
been previously demonstrated that beyond homogenous
subtypes of constitutive and immunoproteasomes, also
mixed proteasome forms exist in various mouse and human
tissues [21, 29].
A major question is whether the difference in protea-
some expression we observed in inflamed mucosa of CD
patients has a strong functional implication in vivo. Many
reports have shown that proteasomes are involved in
regulation of various proteins important for distinct cellular
functions [30, 31]. The replacement of constitutive protea-
somes by immunoproteasomes has been reported to be
crucial for the generation of active NF-κB subunits [17].
Although it has been demonstrated that the immunosubunits
β1i was essential for the processing of NF-κBp r e c u r s o r
protein p105 and for the degradation of the inhibitory protein
IκBα in human lymphocytes, little is known about the
regulating NF-κB activity by the specific proteasomal
subunits. Previously, we have shown that active 20S
proteasomes purified from the inflamed intestine of CD
patients efficiently degraded the inhibitory NF-κBp r o t e i n
IκBα [11]. This data, together with the present study,
suggest that expression and activity of immunoproteasomes
in the inflamed intestine of CD patients might be involved in
the mechanisms underlying immunopathogenesis of this
disease.
In conclusion, our results demonstrate that the develop-
ment of chronic intestinal inflammation in CD leads to
alternations in the subunit composition of 20S proteasomes.
Inflamed colonic tissue of patients with CD showed a
characteristic pattern of 20S proteasomes which was
different from control tissue. Markedly increased mRNA
expression and high protein amounts of immunosubunits
were found in CD as compared to control patients.
Although this finding shows significant effects of Th1/
Th17-mediated inflammation on the composition of protea-
somes, further studies including induction of colitis in β1i,
β2i, and β5i deficient mice are needed to determine
physiological importance of this proteasomal shift. We
suppose that immunoproteasome subunits might be in-
volved in the complex inflammatory response during the
chronic inflammation by increasing NF-κB activity.
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